Literature DB >> 17720251

Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England.

Alan P Johnson1, Pauline Waight, Nick Andrews, Richard Pebody, Robert C George, Elizabeth Miller.   

Abstract

OBJECTIVES: To assess the incidence of pneumococcal meningitis, associated deaths and serotypes of causative pneumococci in England prior to the inclusion of the 7-valent conjugated pneumococcal vaccine in the routine childhood immunisation programme in 2006.
METHODS: Cases were identified using hospital episode statistics (HES) and voluntary reports or submission of isolates to the Health Protection Agency. Mortality data and population estimates were from the Office for National Statistics.
RESULTS: Based on HES, the annual incidence of pneumococcal meningitis was about 1 case per 100,000 population between 1998 and 2005 (an average of approximately 480 cases per year) with case fatality rates increasing from 5% in <15 year olds to 30% in >64 year olds. Enhanced surveillance comprising a combination of voluntary reporting of cases and referral of isolates gave case ascertainment rates of 50-70% compared to those derived from HES, and similar case fatality rates. The age distribution of pneumococcal meningitis was similar with both datasets, infection being reported mostly commonly in children aged less than 5 years, with the highest incidence in children aged 2-11 months. Based on the serotype distribution of isolates obtained in 2005, the serotype coverage afforded by the 7-valent conjugate vaccine is 72% for patients aged less than 2 years.
CONCLUSIONS: These data provide baseline information on the incidence of pneumococcal meningitis and associated mortality, together with the serotypes of infecting strains of pneumococci, which will be critical for evaluation of the public health impact of the 7-valent conjugated pneumococcal vaccine in England.

Entities:  

Mesh:

Year:  2007        PMID: 17720251     DOI: 10.1016/j.jinf.2007.07.009

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  10 in total

Review 1.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

2.  Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales.

Authors:  Bruno Pichon; Shamez N Ladhani; Mary P E Slack; Anne Segonds-Pichon; Nick J Andrews; Pauline A Waight; Elizabeth Miller; Robert George
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

3.  Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  E Pérez-Trallero; J M Marimon; M Ercibengoa; D Vicente; E G Pérez-Yarza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-20       Impact factor: 3.267

4.  Pneumococcal serotypes in children in 4 European countries.

Authors:  Germaine Hanquet; Esther Kissling; Asuncion Fenoll; Robert George; Agnes Lepoutre; Tinne Lernout; David Tarragó; Emmanuelle Varon; Jan Verhaegen
Journal:  Emerg Infect Dis       Date:  2010-09       Impact factor: 6.883

5.  Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany.

Authors:  Matthias Imöhl; Jens Möller; Ralf René Reinert; Stephanie Perniciaro; Mark van der Linden; Orhan Aktas
Journal:  BMC Infect Dis       Date:  2015-02-14       Impact factor: 3.090

Review 6.  A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.

Authors:  James D Chalmers; James Campling; Alison Dicker; Mark Woodhead; Harish Madhava
Journal:  BMC Pulm Med       Date:  2016-05-11       Impact factor: 3.317

7.  Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.

Authors:  Emmanuelle Delgleize; Oscar Leeuwenkamp; Eleni Theodorou; Nicolas Van de Velde
Journal:  BMJ Open       Date:  2016-11-30       Impact factor: 2.692

8.  Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000-June 30, 2016.

Authors:  Godwin Oligbu; Sarah Collins; Abdelmajid Djennad; Carmen L Sheppard; Norman K Fry; Nick J Andrews; Ray Borrow; Mary E Ramsay; Shamez N Ladhani
Journal:  Emerg Infect Dis       Date:  2019-09       Impact factor: 6.883

9.  Receptor for Advanced Glycation End Products (RAGE) Mediates Cognitive Impairment Triggered by Pneumococcal Meningitis.

Authors:  Vijayasree V Giridharan; Jaqueline S Generoso; Allan Collodel; Diogo Dominguini; Cristiano Julio Faller; Flavio Tardin; Gursimrat S Bhatti; Fabricia Petronilho; Felipe Dal-Pizzol; Tatiana Barichello
Journal:  Neurotherapeutics       Date:  2021-01       Impact factor: 7.620

10.  Study protocol: The Dutch 20|30 Postmeningitis study: a cross-sectional follow-up of two historical childhood bacterial meningitis cohorts on long-term outcomes.

Authors:  O El Tahir; R C J de Jonge; S Ouburg; S A Morré; A M van Furth
Journal:  BMC Pediatr       Date:  2019-12-30       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.